相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of Rebound Revascularization as Mode of Escape
Emmanuelle di Tomaso et al.
CANCER RESEARCH (2011)
Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug?
Yihai Cao
INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY (2011)
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer
Nicholas J. Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer
Baohui Han et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Molecular mechanisms and clinical applications of angiogenesis
Peter Carmeliet et al.
NATURE (2011)
Mouse corneal lymphangiogenesis model
Renhai Cao et al.
NATURE PROTOCOLS (2011)
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Peter Carmeliet et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity
Danfang Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Carmustine Wafers (Gliadel) Plus Concomitant Temozolomide Therapy After Resection of Malignant Astrocytoma: Growing Evidence for Safety and Efficacy
Matthew J. McGirt et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Angiogenesis: What can it offer for future medicine?
Yihai Cao
EXPERIMENTAL CELL RESEARCH (2010)
The Anti-angiogenic Peptide, Loop 6, Binds Insulin-like Growth Factor-1 Receptor
Cecilia A. Fernandez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Phase I/II Trial of Metronomic Chemotherapy With Daily Dalteparin and Cyclophosphamide, Twice-Weekly Methotrexate, and Daily Prednisone As Therapy for Metastatic Breast Cancer Using Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor Levels As Markers of Response
Nan Soon Wong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Adipose angiogenesis: quantitative methods to study microvessel growth, regression and remodeling in vivo
Yuan Xue et al.
NATURE PROTOCOLS (2010)
Off-tumor target-beneficial site for antiangiogenic cancer therapy?
Yihai Cao
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases
Yihai Cao
NATURE REVIEWS DRUG DISCOVERY (2010)
First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience
Hans Christoph Bock et al.
NEUROSURGICAL REVIEW (2010)
VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy
Renhai Cao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Optimizing the Delivery of Cancer Drugs that Block Angiogenesis
Yihai Cao et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Hypoxia-Independent Angiogenesis in Adipose Tissues during Cold Acclimation
Yuan Xue et al.
CELL METABOLISM (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination?
Mitchell Kamrava et al.
MOLECULAR BIOSYSTEMS (2009)
Biomarkers of response and resistance to antiangiogenic therapy
Rakesh K. Jain et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance
Yihai Cao et al.
SEMINARS IN CANCER BIOLOGY (2009)
Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: A 10-year institutional experience
Frank J. Attenello et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth, factor receptor-2 levels as a surrogate biomarker for tumor growth
John M. L. Ebos et al.
CANCER RESEARCH (2008)
Urinary biomarkers predict brain tumor presence and response to therapy
Edward R. Smith et al.
CLINICAL CANCER RESEARCH (2008)
Radiation therapy and biological compounds for consolidation therapy in advanced ovarian cancer
A. Auranen et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
Bryan P. Schneider et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Transdermal drug delivery
Mark R. Prausnitz et al.
NATURE BIOTECHNOLOGY (2008)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract
Reshma L. Mahtani et al.
ONCOLOGIST (2008)
Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome
Yuan Xue et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
New frontiers in nanotechnology for cancer treatment
Frank Alexis et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
Bv8 regulates myeloid-cell-dependent tumour angiogenesis
Farbod Shojaei et al.
NATURE (2007)
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
John M. L. Ebos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Molecular and cellular biomarkers for angiogenesis in clinical oncology
Francesco Bertolini et al.
DRUG DISCOVERY TODAY (2007)
Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis
Michael I. Dorrell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Angiogenesis modulates adipogenesis and obesity
Yihai Cao
JOURNAL OF CLINICAL INVESTIGATION (2007)
Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth
Qi Pan et al.
CANCER CELL (2007)
Opinion - Angiogenesis: an organizing principle for drug discovery?
Judah Folkman
NATURE REVIEWS DRUG DISCOVERY (2007)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Michael R. Mancuso et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors
Matthew H. Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Gliadel® wafer in initial surgery for malignant glioma:: long-term follow-up of a multicenter controlled trial
M Westphal et al.
ACTA NEUROCHIRURGICA (2006)
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
T Kamba et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Biodegradable polymer composite grafts promote the survival and differentiation of retinal progenitor cells
M Tomita et al.
STEM CELLS (2005)
Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer
AHG Hansma et al.
ANNALS OF ONCOLOGY (2005)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
Tumor angiogenesis and therapy
Y Cao
BIOMEDICINE & PHARMACOTHERAPY (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
N Ferrara et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Pegaptanib for neovascular age-related macular degeneration
ES Gragoudas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage
R Roy et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice
E Bråkenhielm et al.
CIRCULATION RESEARCH (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2) -: Loop 6 is a novel angiogenesis inhibitor
CA Fernández et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
TSC2 regulates VEGF through mTOR-dependent and -independent pathways
JB Brugarolas et al.
CANCER CELL (2003)
Reversible dementia due to thalidomide therapy for multiple myeloma
AE Morgan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Multi-pulse drug delivery from a resorbable polymeric microchip device
ACR Grayson et al.
NATURE MATERIALS (2003)
Adipose tissue mass can be regulated through the vasculature
MA Rupnick et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Identification of an angiogenic mitogen selective for endocrine gland endothelium
J LeCouter et al.
NATURE (2001)
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
G Klement et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
分享论文
